Follows people with acute ischemic stroke treated with mechanical thrombectomy devices
Observes adults with acute ischemic stroke who receive a Medtronic clot-removal device.
Plain-language title generated from the registry record
Registry title: REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
Key facts
- Where
- Buffalo, Flint, and Houston, United StatesSee the 3 sites
Where in United States
- Buffalo General Medical CenterBuffalo, United StatesTaking people
- McLaren Flint HospitalFlint, United StatesTaking people
- University of Texas Health Science Center at HoustonHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medtronic Neurovascular Clinical Affairs
- Trial code
- NCT07599904
- Record updated
- 28 July 2026
- Original description
Post-Market RegistryRead full original descriptionShow less
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
Post-Market Registry
Inclusion: Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements; Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device* during treatment for acute ischemic stroke; Participant is 18 years of age or older.
Exclusion: Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion; Participant who may be unable to complete follow-up within the registry; Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.